Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9328700 | 0.79 | PDE10A (0.37) | PDE10A | |
| SCHEMBL29018914 | 0.79 | IDO1 (0.39) | PDE10AKDM4E | |
| SCHEMBL77010 | 0.75 | IDO1 (0.35) | — | |
| SCHEMBL2617494 | 0.75 | KDM4E (0.31) | PDE10AKDM4E | |
| SCHEMBL1830615 | 0.73 | PDE10A (0.37) | PDE10A | |
| SCHEMBL801870 | 0.73 | ALDH1A1 (0.39) | PDE10A | |
| SCHEMBL22444361 | 0.72 | KDM4E (0.38) | PDE10AKDM4E | |
| SCHEMBL4314460 | 0.72 | TDP1 (0.35) | PDE10AKDM4E | |
| SCHEMBL440911 | 0.71 | CYP1A2 (0.33) | KDM4E | |
| SCHEMBL14438198 | 0.71 | HSP90AA1 (0.36) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2016-09-15 | — | — | US | disclosed |
| US-9382254-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-07-05 | — | — | US | disclosed |
| US-20150005275-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS. | GALAPAGOS NV (BE) | 2015-01-01 | — | — | US | disclosed |
| US-20140364450-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-12-11 | — | — | US | disclosed |
| US-8735593-B2 | Aminopyridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130245273-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-19 | — | — | US | disclosed |
| US-8410133-B2 | Aminopyridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-8242272-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110021559-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-22 | — | — | US | disclosed |
| CN-100537539-C | Preparation method of 2-chlorin-6-trifluoro picoline | SHANGDONG GUANGHENG CHEMICALS (CN) | 2009-09-09 | — | — | CN | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| CN-101081831-A | Preparation method of 2-chlorin-6-trifluoro picoline | SHANGDONG GUANGHENG CHEMICALS (CN) | 2007-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | PDE10A 107/4885KDM4E 1086/4885 |
| US-20130245273-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP4K5, MAP3K5, MAP3K20 | PDE10A 945/4885KDM4E 1219/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | PDE10A 104/4885KDM4E 1012/4885 |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC3, ABCC5 | PDE10A 465/4885KDM4E 3789/4885 |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | GSK3B, GSK3A, GSKIP | PDE10A 1691/4885KDM4E 425/4885 |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | GSK3B, GSK3A, GSKIP | PDE10A 1691/4885KDM4E 425/4885 |
| US-20110021559-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP4K5, MAP3K5, MAP3K20 | PDE10A 945/4885KDM4E 1219/4885 |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | GSK3B, CDK3, GSK3A | PDE10A 2820/4885KDM4E 1265/4885 |
| US-20150005275-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS. | CFTR, ABCC3, ABCC5 | PDE10A 479/4885KDM4E 3797/4885 |
| US-20140364450-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP4K5, MAP3K5, MAP3K20 | PDE10A 945/4885KDM4E 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.